nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
|
Mamounas, E.P. |
|
|
32 |
8 |
p. 1005-1014 |
artikel |
2 |
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
|
Bellone, S. |
|
|
32 |
8 |
p. 1045-1046 |
artikel |
3 |
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
|
Le Cesne, A. |
|
|
32 |
8 |
p. 1034-1044 |
artikel |
4 |
Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria
|
Gao, J.J. |
|
|
32 |
8 |
p. 950-953 |
artikel |
5 |
Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor ‘Checkpoint inhibition: protecting against or predisposing for second primary tumors?’ by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs
|
Heudel, P. |
|
|
32 |
8 |
p. 1055-1057 |
artikel |
6 |
Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q'
|
Jhaveri, K.L. |
|
|
32 |
8 |
p. 1068 |
artikel |
7 |
Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors'
|
Mirza, M.R. |
|
|
32 |
8 |
p. 1066-1067 |
artikel |
8 |
Editorial Board
|
|
|
|
32 |
8 |
p. iii |
artikel |
9 |
Erratum to ‘Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group’
|
Mandelker, D. |
|
|
32 |
8 |
p. 1069-1071 |
artikel |
10 |
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
|
Emens, L.A. |
|
|
32 |
8 |
p. 983-993 |
artikel |
11 |
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
|
Barrière, J. |
|
|
32 |
8 |
p. 1053-1055 |
artikel |
12 |
‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer
|
Voorwerk, L. |
|
|
32 |
8 |
p. 947-949 |
artikel |
13 |
Important news on nutritional support in cancer patients – but some EFFORT is still ahead
|
Arends, J. |
|
|
32 |
8 |
p. 954-956 |
artikel |
14 |
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
|
Grothey, A. |
|
|
32 |
8 |
p. 959-967 |
artikel |
15 |
Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial
|
Bargetzi, L. |
|
|
32 |
8 |
p. 1025-1033 |
artikel |
16 |
Oncolytic virus in gliomas: a review of human clinical investigations
|
Carpenter, A.B. |
|
|
32 |
8 |
p. 968-982 |
artikel |
17 |
PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials
|
Morice, P.-M. |
|
|
32 |
8 |
p. 1048-1050 |
artikel |
18 |
Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays
|
Page, K. |
|
|
32 |
8 |
p. 1057-1060 |
artikel |
19 |
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|
Miles, D. |
|
|
32 |
8 |
p. 994-1004 |
artikel |
20 |
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
|
Slamon, D.J. |
|
|
32 |
8 |
p. 1015-1024 |
artikel |
21 |
Table of Contents
|
|
|
|
32 |
8 |
p. i-ii |
artikel |
22 |
The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients
|
Street, S. |
|
|
32 |
8 |
p. 1050-1051 |
artikel |
23 |
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
|
Martin, J.E. |
|
|
32 |
8 |
p. 1046-1048 |
artikel |
24 |
Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas
|
Schuetze, S. |
|
|
32 |
8 |
p. 957-958 |
artikel |
25 |
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)
|
Huober, J. |
|
|
32 |
8 |
p. 1061-1062 |
artikel |
26 |
VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
|
Liu, S.V. |
|
|
32 |
8 |
p. 1063-1065 |
artikel |
27 |
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
|
Palich, R. |
|
|
32 |
8 |
p. 1051-1053 |
artikel |